Green tea and Vorapaxar Sulfate

• Generic Name: green tea
• Dosage Forms: n.a.
• Other Brand Names:

Green tea is a product made from the Camellia sinesis plant and it is also known as Camellia theifera, Constituant Polyphénolique de Thé Vert, CPTV, EGCG, Epigallo Catechin Gallate, Extrait de Camellia Sinensis, Extrait de Thé Vert, Extrait de Thea Sinensis, Green Sencha, Green Tea Extract, Green Tea Polyphenolic Fraction, GTP, GTPF, Japanese Tea, Kunecatechins, Poly E, Polyphenon E, PTV, Té Verde, Tea, Tea Extract, Tea Green, Thé de Camillia, Thé Japonais, Thé Vert, Thé Vert Sensha, Thea bohea, Thea sinensis, Thea viridis, Yame Green Tea, Yame Tea, and other names.

Green tea has been used in alternative medicine as a likely effective aid in treating genital warts, high cholesterol, and maintaining mental alertness.

Green tea has been used in alternative medicine as a possibly effective aid in treating clogged arteries, endometrial and ovarian cancer, low blood pressure, osteoporosis, changes in cervical cells due to human papiloma virus (HPV), white patches in the gums and the prevention of Parkinson's disease.

Other uses not proven with research have included various cancers (bladder, esophagus, pancreas, breast, colon, stomach, leukemia, mouth, prostate, lung); acne, heart disease, diabetes, infertility, high blood presure, obesity, respiratory infections, improvement of athletic perfomrance, wrinkles and others.

It is not certain whether green tea is effective in treating any medical condition. Medicinal use of this product has not been approved by the FDA. Green tea should not be used in place of medication prescribed for you by your doctor.

Green tea is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

Green tea may also be used for purposes not listed in this product guide.

• Generic Name: vorapaxar
• Dosage Forms: n.a.
• Other Brand Names: Zontivity

Reduction of the risk of thrombotic cardiovascular events (e.g., cardiovascular death, MI, stroke, urgent coronary revascularization) in patients with a history of MI or with peripheral arterial disease (PAD).

Use in conjunction with aspirin and/or clopidogrel; data lacking on use of vorapaxar in combination with other antiplatelet agents (e.g., prasugrel, ticagrelor) or as monotherapy.

Efficacy and safety established in patients with stable atherosclerotic disease; favorable benefit versus risk not established in the setting of acute coronary syndrome (ACS). (See Acute Coronary Syndrome under Uses.)

The American Heart Association (AHA), American College of Cardiology Foundation (ACCF), American College of Chest Physicians (ACCP), and other experts recommend long-term antiplatelet therapy (e.g., aspirin and/or clopidogrel) in patients with established coronary artery disease. Long-term antiplatelet therapy (e.g., clopidogrel, aspirin) also recommended in patients with symptomatic PAD, including those with intermittent claudication, critical limb ischemia, or prior revascularization or amputation of the lower extremity. When added to aspirin and/or clopidogrel therapy, vorapaxar reduces cardiovascular events (e.g., composite outcome of cardiovascular death, MI, stroke, and urgent coronary revascularization) but increases risk of bleeding, including intracranial hemorrhage.

Balance incremental benefits against risk of bleeding; certain patients (e.g., those with a history of MI who are at high risk of recurrence but low risk of bleeding and who have not had a previous stroke or TIA) may have greater potential for net clinical benefits. Overall risk-benefit of vorapaxar in routine clinical practice remains to be fully elucidated.

Has been used in patients with ACS; however, current evidence suggests that the addition of vorapaxar to standard antiplatelet therapy in such patients does not substantially reduce rate of ischemic events but substantially increases risk of clinically important bleeding.

Many clinicians currently advise against use of vorapaxar in patients with ACS.